Skip to content

Construction and Evaluation of a Comprehensive Digital Intelligent Platform for Thrombosis Prevention and Management Across the Entire Process

Construction and Evaluation of a Comprehensive Digital Intelligent Platform for Thrombosis Prevention and Management Across the Entire Process

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500114307
Enrollment
Unknown
Registered
2025-12-10
Start date
2026-01-01
Completion date
Unknown
Last updated
2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart valve disease

Interventions

The new anticoagulation management group:Intelligent early warning system
The traditional anticoagulation management group:None

Sponsors

Hainan General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >=18 years old, both sexes; 2. Patients using anticoagulant drugs; 3. The patient had a smart phone in accordance with the operating environment of the study software program, and was able to use the study software program through guidance.

Exclusion criteria

Exclusion criteria: 1.Patients without indications for antithrombotic drugs;

Design outcomes

Primary

MeasureTime frame
Death rate;Hospital-acquired bleeding complications in patients on anticoagulation therapy;Thrombotic event;Number of days meeting the standards;Number of qualified attempts;International standardization ratio compliance rate;Disease cure rate;Incidence of serious adverse reactions;The required time to meet the standard;Recurrent disease rate;

Secondary

MeasureTime frame
Length of hospital stay;Average cost per unit;Recognition score;Number of days during the perioperative period when anticoagulant drugs were discontinued;The reporting rate of adverse events related to anticoagulant drugs;The number of anticoagulant drugs used during the perioperative period;The total number of anticoagulant drugs used;Indirect costs;Direct expense;The proportion of patients who received medication for postoperative venous thromboembolism assessment;

Countries

China

Contacts

Public ContactDanna Wu

Hainan General Hospital

wudannachangchang@163.com+86 898 68622576

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026